M&T Bank Corp raised its holdings in shares of Danaher Co. (NYSE:DHR) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 401,834 shares of the conglomerate’s stock after buying an additional 1,180 shares during the quarter. M&T Bank Corp owned about 0.06% of Danaher worth $37,297,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock valued at $3,501,206,000 after purchasing an additional 520,776 shares during the period. BlackRock Inc. increased its position in shares of Danaher by 3.2% during the second quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock valued at $3,308,239,000 after purchasing an additional 1,233,876 shares during the period. FMR LLC increased its position in shares of Danaher by 0.9% during the second quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock valued at $1,656,100,000 after purchasing an additional 183,183 shares during the period. Parnassus Investments CA increased its position in shares of Danaher by 0.3% during the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock valued at $840,351,000 after purchasing an additional 29,381 shares during the period. Finally, Flossbach Von Storch AG increased its position in shares of Danaher by 17.2% during the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock valued at $581,324,000 after purchasing an additional 994,902 shares during the period. Institutional investors own 75.88% of the company’s stock.
Danaher Co. (NYSE DHR) opened at $97.54 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05. The company has a market capitalization of $67,897.60, a price-to-earnings ratio of 27.63, a price-to-earnings-growth ratio of 2.05 and a beta of 1.04. Danaher Co. has a one year low of $78.97 and a one year high of $104.82.
Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.03. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The business’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.05 earnings per share. sell-side analysts expect that Danaher Co. will post 4.37 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend was Thursday, December 28th. Danaher’s dividend payout ratio is currently 15.86%.
In other news, SVP Angela S. Lalor sold 42,988 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the transaction, the senior vice president now owns 82,008 shares of the company’s stock, valued at $8,388,598.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total value of $13,375,285.30. Following the transaction, the executive vice president now directly owns 270,523 shares in the company, valued at approximately $27,606,872.15. The disclosure for this sale can be found here. In the last three months, insiders sold 237,043 shares of company stock worth $24,194,886. Insiders own 12.20% of the company’s stock.
A number of research firms have recently issued reports on DHR. Barclays began coverage on Danaher in a research report on Thursday. They set an “overweight” rating and a $110.00 price objective on the stock. Argus boosted their price objective on Danaher from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Royal Bank of Canada reiterated a “hold” rating and issued a $98.00 price target on shares of Danaher in a research report on Wednesday, January 31st. Stifel Nicolaus upped their price target on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Morgan Stanley upped their price target on Danaher from $103.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $100.68.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/17/danaher-co-dhr-shares-bought-by-mt-bank-corp.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.